Whitehawk Therapeutics
WHWK
67 hedge funds and large institutions have $101M invested in Whitehawk Therapeutics in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 12 closing their positions.
3,890% more call options, than puts
Call options by funds: $399K | Put options by funds: $10K
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.17% less ownership
Funds ownership: 58.68% → 58.51% (-0.17%)
4% less funds holding
Funds holding: 70 → 67 (-3)
5% less capital invested
Capital invested by funds: $107M → $101M (-$5.77M)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.59M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$1.46M |
| 3 |
BlackRock
New York
|
+$1.1M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$777K |
| 5 |
LPC
Lion Point Capital
New York
|
+$641K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.27M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$2.3M |
| 3 |
Renaissance Technologies
New York
|
-$945K |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$550K |
| 5 |
Millennium Management
New York
|
-$524K |
WHWK Hedge Fund Activity: Q2 2023 in Review
67 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q2 2023, worth a combined $101M — down 5.4% from $107M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of WHWK and 9 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 26 added.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $2.59M. The largest seller was RA Capital Management, exiting entirely with an estimated $4.27M sold.
- 67 institutional investors held Whitehawk Therapeutics (WHWK) as of Q2 2023, down from 70 in Q1 2023.
- Funds reported $101M of Whitehawk Therapeutics stock for Q2 2023, down 5.4% quarter-over-quarter.
- 9 funds opened new Whitehawk Therapeutics positions in Q2 2023 and 12 closed out, a net change of -3 holders.
- The largest Whitehawk Therapeutics buyer in Q2 2023 was Soleus Capital Management, an estimated $2.59M added.
- The largest Whitehawk Therapeutics seller in Q2 2023 was RA Capital Management, an estimated $4.27M sold.
Based on aggregated 13F filings for Q2 2023.